Skip to content

OBJECTIVES: To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial

Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. The objective of this open-label prospective unblinded study was to evaluate the efficacy of ustekinumab in nail psoriasis and the improvement of patient quality of life (QoL). To assess improvement in fingernail psoriasis with ustekinumab treatment in PHOENIX 1. To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4.

OBJECTIVES: To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial 2Objectives: The TRANSIT study aimed to assess the efficacy and safety of two methotrexate-to-ustekinumab transition strategies. To assess improvement in fingernail psoriasis with ustekinumab treatment in PHOENIX 1. Life in a Population Treated with Ustekinumab for Cutaneous Psoriasis: An Open Prospective Unblinded Study. Background: The objective of this open-label prospective unblinded study was to evaluate the efficacy of ustekinumab in nail psoriasis and the improvement of patient quality of life (QoL). Outcome measures were assessed at baseline and at weeks 4, 16, 28 and 40 using the nail psoriasis severity index (NAPSI). Nail psoriasis continued to improve in patients in all groups treated with ustekinumab over time after the placebo-controlled portion of the study, and improvements were sustained through 1 year. For that purpose, each nail is divided into four quadrants to be assessed for the presence of any psoriatic change originating from both the nail matrix (pitting, leukonychia, and nail plate crumbling) and the nail bed (oil drop discoloration, onycholysis, hyperkeratosis, and splinter hemorrhages). Nonetheless, the objective quantitative assessments of nail improvement under ustekinumab therapy have not yet been reported.

For patients with significant skin and nail disease, adalimumab, etanercept, and ustekinumab are strongly recommended, and methotrexate, acitretin, infliximab, and apremilast are recommended. Clinical trial data are limited, and results are reported inconsistently, making comparisons among treatment options difficult. View Psoriasis and Psoriatic Disorders clinical trial results here. Patients received doses of 1 mg/kg or 2 mg/kg or placebo administered once a week for 12 weeks. One such example is the Psoriasis Longitudinal Assessment and Registry (PSOLAR), an 8-year international study sponsored by Janssen Scientific Affairs, LLC to prospectively enroll a targeted 12,000 patients who are receiving or who are candidates for systemic therapies. For ustekinumab-randomized patients, HRQOL improvements were sustained through week 28.

Stelara 3 New Studies

These trials are registered with ClinicalTrials.gov, numbers NCT01597245 and NCT01646177. These studies show that selectively neutralising interleukin 17A with a high affinity antibody potentially gives patients with psoriasis a new and effective biological therapy option. Objectives. Many therapies for psoriasis treatment improve HRQOL 810. Wang Y, Krueger GG: Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Jama Network